1834-91-9

Usage

Uses

Used in Pharmaceutical Industry:
Ethanone, 1-(2-hydroxy-4-nitrophenyl)is utilized as a key intermediate in the synthesis of pharmaceuticals. Its functional groups facilitate the creation of a wide range of medicinal compounds, making it an essential component in drug development.
Used in Dye Industry:
In the dye industry, Ethanone, 1-(2-hydroxy-4-nitrophenyl)serves as a building block for the production of various dyes. Its chemical structure allows for the development of dyes with specific color properties and applications.
Used in Organic Synthesis:
Ethanone, 1-(2-hydroxy-4-nitrophenyl)is used as a versatile intermediate in organic synthesis. Its nitro and hydroxyl groups enable the formation of a variety of organic substances, contributing to the advancement of organic chemistry and the creation of new compounds with diverse applications.

Upstream product

• 1523-06-4 3-nitrophenyl acetate 
• 90564-14-0 1-(2-methoxy-4-nitrophenyl)ethanone 
• 99060-88-5 1-(2-methoxymethoxy-4-nitro-phenyl)-ethanone 
• 554-84-7 meta-nitrophenol 
• 90005-90-6 2-ethyl-5-nitro-phenol 
• 90610-19-8 2-ethyl-5-nitro-anisole 
• 20191-74-6 2-ethyl-5-nitroaniline 
• 99076-45-6 1-ethyl-2-methoxymethoxy-4-nitro-benzene 
• 2033-24-1 cycl-isopropylidene malonate 
• 619-19-2 2-hydroxy-4-nitrobenzoic acid 
• 25115-58-6 1-(4-nitrophenyl)ethan-1-one O-methyl oxime 
• 100-19-6 (4-nitrophenyl)ethanone 

Downstream Products

• 90564-14-0 1-(2-methoxy-4-nitrophenyl)ethanone 
• 5230-72-8 2-bromo-1-(2-hydroxy-4-nitro-phenyl)-ethanone 
• 856814-69-2 1-benzo[1,3]dioxol-5-yl-3-(2-hydroxy-4-nitro-phenyl)-propane-1,3-dione 
• 52923-32-7 2'-hydroxy-4'-nitro-trans-chalcone 
• 100961-78-2 1-(2-benzoyloxy-4-nitro-phenyl)-ethanone 
• 107918-18-3 (E)-3-(3,4-dihydroxyphenyl)-1-(2-hydroxy-4-nitrophenyl)prop-2-en-1-one 
• 118761-27-6 1-(2-hydroxy-4-nitrophenyl)-3-(2-thienyl)-2-propen-1-one 
• 118761-29-8 1-(2-hydroxy-4-nitrophenyl)-3-(3-thienyl)-2-propen-1-one 
• 100965-09-1 1-(2-benzoyloxy-4-nitro-phenyl)-2-bromo-ethanone 
• 1247949-36-5 2-(1-iminoethyl)-5-nitrophenol 
• 1382679-82-4 2-(1-(4-methoxyphenylimino)ethyl)-5-nitrophenol 
• 882816-71-9 2'-hydroxy-4-nitroacetophenone thiosemicarbazone 
• 1498298-40-0 2-hydroxy-4-nitroacetophenone hydrazone 
• 99488-18-3 4-(2-Hydroxy-4-nitro-benzoyl)-6-(7-nitro-4-oxo-4H-chromen-3-yl)-pyridine-2-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Reusable Palladium Nanoparticles Catalyzed Oxime Ether Directed Mono Ortho-Hydroxylation under Phosphine Free Neutral Condition

An efficient, reusable and stable binaphthyl stabilized Pd-nanoparticles (Pd-BNP) catalyzed the direct ortho-C?H hydroxylation of acetophenone oxime ethers under neutral and phosphine ligand-free condition has been developed. A readily available, economic, safe and greener oxidant oxone has been used in this direct ortho-hydroxylation. The scope of the reaction has been studied with various acetophenone oxime ethers including electron rich to electron deficient system and the reaction afforded only mono hydroxylated products in a highly regioselective manner. Several control experiment results confirmed that the oxone is the hydroxyl source. The Pd-BNP catalyst has been reused up to five times. The heterogeneous test confirmed that the reaction is catalyzed by the heterogeneous Pd-BNP catalyst. (Figure presented.).

QSAR studies of paeonol analogues for inhibition of platelet aggregation

Various paeonol analogues were synthesized and tested in vitro as inhibitors of platelet aggregation. Structural properties (or descriptors) of paeonol analogues were calculated and the structure-activity relationships were determined. Several multiple linear and nonlinear regression models and back-propagation neural network model were tested and the latter using relative positive charge, hydration energy, and hydrophilic factor as inputs gave the best data fitting with R2 = 0.89 and qpre2=0.66. The correlation coefficient between antiplatelet inhibition activity with an interaction energy between the paeonol compounds with COX-1 enzyme is only 0.39.

2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Selected 2-arylacetic acids, their derivatives and pharmaceutical compositions that contain these compounds are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. In particular, 2(ortho)-substituted arylacetic acids or their derivatives, such as amides and sulfonamides, lack cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.

Synthesis and in-vitro evaluation of platelet aggregation inhibitory activity of paeonol and its analogues

Paeonol (1-(2-hydroxy-4-methoxyphenyl)ethanone) and a series of substituted 1-(2-hydroxyphenyl)ethanone derivatives were synthesized and screened as inhibitors of platelet aggregation. The compounds with the greatest anti-platelet potential among the series tested were 1-(2,5-dihydroxyphenyl)ethanone (65.36% inhibition at 300 μM against 5 μM ADP), paeonol(36.31%), 1-(2-hydroxy-5-methoxyphenyl)ethanone (24.47%), 1-(2-hydroxy-5-nitrophenyl) ethanone (30.40%) and 1-(5-chloro-2-hydroxy-4-methylphenyl)ethanone (24.43%).